Farm Comunitarios. 2023 Jan 02;15(1):56-63. doi: 10.33620/FC.2173-9218.(2023).06

Effect of eye drops based on hyaluronic acid, Aloe vera and Centella asiatica on quality of life of patients with dry eye

Vicen-Carbó I1, Corretger-Bobis E2, García-del-Cerro C3, Sotelo-Prats L4, Barturen-Echeverria B5, García-Marqueta E6, Homs-Balló M7, Rubis-Marin G8, Pegueroles-Vallés E9, Duart-Castells L10
1. Community pharmacist. Vicen Carbó Pharmacy (Barcelona). 2. Community pharmacist (Girona). 3. Community pharmacist. García del Cerro Pharmacy (Barcelona). 4. Community pharmacist. Lluc Sotelo Prats Pharmacy (Badalona). 5. Community pharmacist. Marina Pharmacy (Barcelona). 6. Community pharmacist. Marqueta Garcia Pharmacy (Barcelona). 7. Community pharmacist. Marta Homs Balló Pharmacy (Barcelona). 8. Community pharmacist. Rubís Pharmacy (Barcelona). 9. Degree in Pharmacy. 10. Graduate in Pharmacy. MSc, Ph.
Vicen-Carbó I, Corretger-Bobis E, García-del-Cerro C, Sotelo-Prats L, Barturen-Echeverria B, García-Marqueta E, Homs-Balló M, Rubis-Marin G, Pegueroles-Vallés E, Duart-Castells L. Effect of eye drops based on hyaluronic acid, Aloe vera and Centella asiatica on quality of life of patients with dry eye. Farm Comunitarios. 2023 Jan 02;15(1):56-63. doi: 10.33620/FC.2173-9218.(2023).06
Abstract : 

Introduction: The dry eye disease (DED) is a common disease and a frequent reason for consultation at community pharmacy. DED has a high impact on patients’ quality of life (QoL); therefore, an appropriate treatment should aim to improve it. Artificial tears constitute the cornerstone for DED management and the main treatment recommended by pharmaceutical indication. 

Objective: To study the effect of eyedrops based on hyaluronic acid, Centella asiatica and Aloe vera on the QoL of patients with DED. In parallel, treatment adherence, tolerance and safety of the product were evaluated.

Methods: Post-authorization, open, prospective and multicentric clinical study. Patients received the treatment for 60 days. To study the effect on QoL, patients completed the OSDI© questionnaire before starting the treatment, and at 30 and 60 days of treatment. Treatment adherence was assessed by means of units’ reconciliation and the safety, through adverse events monitoring. 

Results: Patients treated with eyedrops, Intention to treat (ITT, n=44), obtained clinically important improvements in their QoL, symptomatology and visual function, as the OSDI© score decreased from 32.80 (DE=23.00) (severe DED) at baseline to 12.64 (DE=15.32) (normal status, p<0.001), and 9.22 (DE=10.37) (normal status, p<0.001), at 30 and 60 days, respectively. Over 70% of patients adhered to the treatment. The safety profile was favourable. Four Mild intensity ocular adverse events were observed. No security concerns were raised.

Conclusions: The studied eyedrops might be an effective and safe treatment option to improve the QoL of patients with DED.

Editor: © SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. 
Copyright© SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/

Share

-

Manual for authors

Journal Information